Psoriasis

Benjamin Lockshin, MD, FAAD, discussed combining biologics with topical innovations like tapinarof and roflumilast to address plaque psoriasis treatment gaps.

The company’s phase 3 trials show JNJ-2113 significantly improves skin clearance and tolerability for patients with moderate to severe psoriasis.

November's cover feature highlights the revolutionary role of artificial intelligence in the development of zasocitinib for the treatment of psoriasis.

Higher stress hyperglycemia ratios are linked to elevated mortality risk in psoriasis, highlighting its systemic nature and need for intensive care.

4 case histories highlight the physical and psychosocial burden of generalized pustular psoriasis.

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.

In a recent Dermatology Times DermView video series, “Advancing Care in Pediatric Plaque Psoriasis: Emerging Treatments and Management Strategies," Karan Lal, DO, and Helen Shin, MD, discuss pediatric psoriasis and its prevalence.

Song stressed the need for careful therapy selection in patients with comorbid conditions to avoid exacerbating health issues.

Historically, research and clinical practice often have overlooked the distinct manifestations and treatment needs of patients with skin of color who have psoriasis.

The new delivery systems for bimekizumab-bkzx represent an upgrade over previous 1 mL options, reducing the frequency of injections required.

Omar Noor, MD, FAAD, hosted a live Case-Based Roundtable discussion with local dermatology clinicians to discuss 2 patients with plaque psoriasis and what would be the ideal topical treatment for each.

Researchers behind the study emphasized the urgent need to enhance the diagnostic skills of primary care practitioners to improve early detection of psoriasis.

Otulfi from Formycon and Fresenius Kabi was approved simultaneously in the US and the European Union. In the US, it will launch in February 2025.

The IL-17 inhibitor demonstrated biologic-level efficacy in moderate to severe plaque psoriasis.

Over 70% of patients achieved clear or minimal skin by week 48, with a 90% retention rate in diverse patients with PsO.

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

While researchers found both therapies effective in long-term use, they stated secukinumab showed quicker improvements in QoL.

Enhanced education can reduce uncertainty among both patients and providers, with pharmacists playing a key role as primary sources of patient information.

This marks the first head-to-head trial of an IL-17A/F inhibitor against an IL-23 inhibitor in psoriatic arthritis treatment.

The company plans to release full 52-week OLE data for ESK-001 in early 2025, building on positive interim results.

The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.

Through collaboration with Nimbus Therapeutics and Schrodinger, zasocitinib’s AI-driven design maximizes its fit within the targeted enzyme.

Mona Shahriari, MD, FAAD, shared insights into prevalence, clinical presentations, increasing research diversity, and advocating for representation.

Researchers presented interim 3-year results from the European SERENA study.

Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.

The FDA has set a PDUFA target action date of May 22, 2025.